The US Food and Drug Administration (FDA) has updated the emergency use authorization (EUA) for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab and suspended its use to treat Covid-19.
Sotrovimab is an investigational monoclonal antibody that binds to the epitope of the SARS-CoV-2 virus to neutralise it.
The regulatory authority noted that the antibody is unlikely to be effective against the Omicron BA.2 sub-variant, which is causing a rise in the number of Covid-19 cases in the region.
The proportion of the sub-variant-caused Covid-19 cases is more than 50% in all Health and Human Services (HHS) US regions, the Centers for Disease Control and Prevention (CDC) Nowcast data showed.
In a statement, the FDA said: “Data included in the health care provider fact sheet show the authorised dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
“Due to these data, sotrovimab is not authorised in any US state or territory at this time.”
In March this year, the regulatory agency updated the EUA Fact Sheet to limit the use of sotrovimab for Covid-19, due to the sub-variant.
The companies were previously preparing a data package to support the use of a higher dose of sotrovimab against the subvariant.
GSK and Vir will also submit these data to several regulatory and health agencies across the globe.
Sotrovimab had obtained FDA EUA to treat mild-to-moderate Covid-19 in adult and paediatric patients of the age 12 years or above, in May last year.
It was indicated for people who are at high risk of disease progression, including hospitalisation or mortality.
